vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and NNN REIT, INC. (NNN). Click either name above to swap in a different company.
NNN REIT, INC. is the larger business by last-quarter revenue ($240.4M vs $168.4M, roughly 1.4× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 4.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.3%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
NNN Reit, Inc. is a real estate investment trust that invests primarily in restaurant properties that are subject to long-term triple net leases, usually under leaseback arrangements. It is organized in Maryland with its principal office in Orlando, Florida.
ESPR vs NNN — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $240.4M |
| Net Profit | — | $94.0M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 61.0% |
| Net Margin | — | 39.1% |
| Revenue YoY | 143.7% | 4.1% |
| Net Profit YoY | — | -2.6% |
| EPS (diluted) | $0.32 | $0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $240.4M | ||
| Q4 25 | $168.4M | $238.4M | ||
| Q3 25 | $87.3M | $230.2M | ||
| Q2 25 | $82.4M | $226.8M | ||
| Q1 25 | $65.0M | $230.9M | ||
| Q4 24 | $69.1M | $218.5M | ||
| Q3 24 | $51.6M | $218.6M | ||
| Q2 24 | $73.8M | $216.8M |
| Q1 26 | — | $94.0M | ||
| Q4 25 | — | $96.0M | ||
| Q3 25 | $-31.3M | $96.8M | ||
| Q2 25 | $-12.7M | $100.5M | ||
| Q1 25 | $-40.5M | $96.5M | ||
| Q4 24 | — | $97.9M | ||
| Q3 24 | $-29.5M | $97.9M | ||
| Q2 24 | $-61.9M | $106.7M |
| Q1 26 | — | 61.0% | ||
| Q4 25 | 50.6% | 62.3% | ||
| Q3 25 | -11.4% | 64.0% | ||
| Q2 25 | 8.6% | 66.0% | ||
| Q1 25 | -34.0% | 62.3% | ||
| Q4 24 | -6.4% | 65.8% | ||
| Q3 24 | -31.0% | 65.7% | ||
| Q2 24 | 3.5% | 70.2% |
| Q1 26 | — | 39.1% | ||
| Q4 25 | — | 40.2% | ||
| Q3 25 | -35.9% | 42.1% | ||
| Q2 25 | -15.4% | 44.3% | ||
| Q1 25 | -62.2% | 41.8% | ||
| Q4 24 | — | 44.8% | ||
| Q3 24 | -57.2% | 44.8% | ||
| Q2 24 | -83.9% | 49.2% |
| Q1 26 | — | $0.50 | ||
| Q4 25 | $0.32 | $0.51 | ||
| Q3 25 | $-0.16 | $0.51 | ||
| Q2 25 | $-0.06 | $0.54 | ||
| Q1 25 | $-0.21 | $0.51 | ||
| Q4 24 | $-0.14 | $0.52 | ||
| Q3 24 | $-0.15 | $0.53 | ||
| Q2 24 | $-0.33 | $0.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $4.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $4.4B |
| Total Assets | $465.9M | $9.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $4.6M | ||
| Q4 25 | $167.9M | $5.0M | ||
| Q3 25 | $92.4M | $157.9M | ||
| Q2 25 | $86.1M | $6.0M | ||
| Q1 25 | $114.6M | $5.1M | ||
| Q4 24 | $144.8M | $8.7M | ||
| Q3 24 | $144.7M | $173.5M | ||
| Q2 24 | $189.3M | $2.1M |
| Q1 26 | — | $4.4B | ||
| Q4 25 | $-302.0M | $4.4B | ||
| Q3 25 | $-451.4M | $4.4B | ||
| Q2 25 | $-433.5M | $4.4B | ||
| Q1 25 | $-426.2M | $4.4B | ||
| Q4 24 | $-388.7M | $4.4B | ||
| Q3 24 | $-370.2M | $4.4B | ||
| Q2 24 | $-344.2M | $4.2B |
| Q1 26 | — | $9.4B | ||
| Q4 25 | $465.9M | $9.4B | ||
| Q3 25 | $364.0M | $9.5B | ||
| Q2 25 | $347.1M | $9.1B | ||
| Q1 25 | $324.0M | $9.0B | ||
| Q4 24 | $343.8M | $8.9B | ||
| Q3 24 | $314.1M | $8.9B | ||
| Q2 24 | $352.3M | $8.7B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $667.1M | ||
| Q3 25 | $-4.3M | $218.3M | ||
| Q2 25 | $-31.4M | $119.4M | ||
| Q1 25 | $-22.6M | $203.3M | ||
| Q4 24 | $-35.0M | $635.5M | ||
| Q3 24 | $-35.3M | $206.6M | ||
| Q2 24 | $-7.2M | $120.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 6.95× | ||
| Q3 25 | — | 2.25× | ||
| Q2 25 | — | 1.19× | ||
| Q1 25 | — | 2.11× | ||
| Q4 24 | — | 6.49× | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 1.13× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
NNN
Segment breakdown not available.
